[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].
Identifieur interne : 000195 ( Main/Exploration ); précédent : 000194; suivant : 000196[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].
Auteurs : H. Javelot [France] ; P-M Llorca [France] ; G. Meyer [France] ; P. Fossati [France] ; E. Haffen [France]Source :
- L'Encephale [ 0013-7006 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (effets indésirables), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Anxiolytiques (effets indésirables), Anxiolytiques (usage thérapeutique), Appréciation des risques (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Comorbidité (MeSH), Dyspnée (induit chimiquement), Dyspnée (étiologie), Humains (MeSH), Hypnotiques et sédatifs (effets indésirables), Hypnotiques et sédatifs (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Psychoanaleptiques (effets indésirables), Psychoanaleptiques (pharmacologie), Psychoanaleptiques (usage thérapeutique), Repositionnement des médicaments (MeSH), Respiration (effets des médicaments et des substances chimiques), Troubles mentaux (traitement médicamenteux), Troubles mentaux (épidémiologie).
- MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus, Respiration.
- effets indésirables : Antiviraux, Anxiolytiques, Hypnotiques et sédatifs, Psychoanaleptiques.
- induit chimiquement : Dyspnée.
- pharmacologie : Antiviraux, Psychoanaleptiques.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale, Troubles mentaux.
- usage thérapeutique : Antiviraux, Anxiolytiques, Hypnotiques et sédatifs, Psychoanaleptiques.
- épidémiologie : Infections à coronavirus, Pneumopathie virale, Troubles mentaux.
- étiologie : Dyspnée.
- Appréciation des risques, Comorbidité, Humains, Pandémies, Repositionnement des médicaments.
English descriptors
- KwdEn :
- Anti-Anxiety Agents (adverse effects), Anti-Anxiety Agents (therapeutic use), Antiviral Agents (adverse effects), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Comorbidity (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Drug Repositioning (MeSH), Dyspnea (chemically induced), Dyspnea (etiology), Humans (MeSH), Hypnotics and Sedatives (adverse effects), Hypnotics and Sedatives (therapeutic use), Mental Disorders (drug therapy), Mental Disorders (epidemiology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Psychotropic Drugs (adverse effects), Psychotropic Drugs (pharmacology), Psychotropic Drugs (therapeutic use), Respiration (drug effects), Risk Assessment (MeSH).
- MESH :
- chemical , adverse effects : Anti-Anxiety Agents, Antiviral Agents, Hypnotics and Sedatives, Psychotropic Drugs.
- chemical , pharmacology : Antiviral Agents, Psychotropic Drugs.
- chemical , therapeutic use : Anti-Anxiety Agents, Antiviral Agents, Hypnotics and Sedatives, Psychotropic Drugs.
- chemically induced : Dyspnea.
- drug effects : Betacoronavirus, Respiration.
- drug therapy : Coronavirus Infections, Mental Disorders, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Mental Disorders, Pneumonia, Viral.
- etiology : Dyspnea.
- Comorbidity, Drug Repositioning, Humans, Pandemics, Risk Assessment.
Abstract
French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders.
DOI: 10.1016/j.encep.2020.04.009
PubMed: 32360037
PubMed Central: PMC7177137
Affiliations:
- France
- Alsace (région administrative), Bourgogne-Franche-Comté, Franche-Comté, Grand Est, Île-de-France
- Besançon, Paris, Strasbourg
- Université de Franche-Comté, Université de Strasbourg
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].</title><author><name sortKey="Javelot, H" sort="Javelot, H" uniqKey="Javelot H" first="H" last="Javelot">H. Javelot</name><affiliation wicri:level="4"><nlm:affiliation>Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Llorca, P M" sort="Llorca, P M" uniqKey="Llorca P" first="P-M" last="Llorca">P-M Llorca</name><affiliation wicri:level="1"><nlm:affiliation>CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne</wicri:regionArea><wicri:noRegion>Université Clermont Auvergne</wicri:noRegion><wicri:noRegion>Université Clermont Auvergne</wicri:noRegion></affiliation></author><author><name sortKey="Meyer, G" sort="Meyer, G" uniqKey="Meyer G" first="G" last="Meyer">G. Meyer</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU de Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Fossati, P" sort="Fossati, P" uniqKey="Fossati P" first="P" last="Fossati">P. Fossati</name><affiliation wicri:level="3"><nlm:affiliation>Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Haffen, E" sort="Haffen, E" uniqKey="Haffen E" first="E" last="Haffen">E. Haffen</name><affiliation wicri:level="4"><nlm:affiliation>Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName><orgName type="university">Université de Franche-Comté</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32360037</idno><idno type="pmid">32360037</idno><idno type="doi">10.1016/j.encep.2020.04.009</idno><idno type="pmc">PMC7177137</idno><idno type="wicri:Area/Main/Corpus">001489</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001489</idno><idno type="wicri:Area/Main/Curation">001489</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001489</idno><idno type="wicri:Area/Main/Exploration">001489</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].</title><author><name sortKey="Javelot, H" sort="Javelot, H" uniqKey="Javelot H" first="H" last="Javelot">H. Javelot</name><affiliation wicri:level="4"><nlm:affiliation>Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Llorca, P M" sort="Llorca, P M" uniqKey="Llorca P" first="P-M" last="Llorca">P-M Llorca</name><affiliation wicri:level="1"><nlm:affiliation>CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne</wicri:regionArea><wicri:noRegion>Université Clermont Auvergne</wicri:noRegion><wicri:noRegion>Université Clermont Auvergne</wicri:noRegion></affiliation></author><author><name sortKey="Meyer, G" sort="Meyer, G" uniqKey="Meyer G" first="G" last="Meyer">G. Meyer</name><affiliation wicri:level="3"><nlm:affiliation>Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU de Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Fossati, P" sort="Fossati, P" uniqKey="Fossati P" first="P" last="Fossati">P. Fossati</name><affiliation wicri:level="3"><nlm:affiliation>Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Haffen, E" sort="Haffen, E" uniqKey="Haffen E" first="E" last="Haffen">E. Haffen</name><affiliation wicri:level="4"><nlm:affiliation>Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName><orgName type="university">Université de Franche-Comté</orgName></affiliation></author></analytic><series><title level="j">L'Encephale</title><idno type="ISSN">0013-7006</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Anxiety Agents (adverse effects)</term><term>Anti-Anxiety Agents (therapeutic use)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Drug Repositioning (MeSH)</term><term>Dyspnea (chemically induced)</term><term>Dyspnea (etiology)</term><term>Humans (MeSH)</term><term>Hypnotics and Sedatives (adverse effects)</term><term>Hypnotics and Sedatives (therapeutic use)</term><term>Mental Disorders (drug therapy)</term><term>Mental Disorders (epidemiology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Psychotropic Drugs (adverse effects)</term><term>Psychotropic Drugs (pharmacology)</term><term>Psychotropic Drugs (therapeutic use)</term><term>Respiration (drug effects)</term><term>Risk Assessment (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Anxiolytiques (effets indésirables)</term><term>Anxiolytiques (usage thérapeutique)</term><term>Appréciation des risques (MeSH)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Comorbidité (MeSH)</term><term>Dyspnée (induit chimiquement)</term><term>Dyspnée (étiologie)</term><term>Humains (MeSH)</term><term>Hypnotiques et sédatifs (effets indésirables)</term><term>Hypnotiques et sédatifs (usage thérapeutique)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Psychoanaleptiques (effets indésirables)</term><term>Psychoanaleptiques (pharmacologie)</term><term>Psychoanaleptiques (usage thérapeutique)</term><term>Repositionnement des médicaments (MeSH)</term><term>Respiration (effets des médicaments et des substances chimiques)</term><term>Troubles mentaux (traitement médicamenteux)</term><term>Troubles mentaux (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Anxiety Agents</term><term>Antiviral Agents</term><term>Hypnotics and Sedatives</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term><term>Antiviral Agents</term><term>Hypnotics and Sedatives</term><term>Psychotropic Drugs</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dyspnea</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term><term>Respiration</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Mental Disorders</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term><term>Respiration</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Anxiolytiques</term><term>Hypnotiques et sédatifs</term><term>Psychoanaleptiques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Mental Disorders</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyspnea</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Dyspnée</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Psychoanaleptiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Troubles mentaux</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Anxiolytiques</term><term>Hypnotiques et sédatifs</term><term>Psychoanaleptiques</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Troubles mentaux</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Dyspnée</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Comorbidity</term><term>Drug Repositioning</term><term>Humans</term><term>Pandemics</term><term>Risk Assessment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term><term>Comorbidité</term><term>Humains</term><term>Pandémies</term><term>Repositionnement des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32360037</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>3S</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].</ArticleTitle><Pagination><MedlinePgn>S116-S118</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(20)30077-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2020.04.009</ELocationID><Abstract><AbstractText>French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders.</AbstractText><CopyrightInformation>Copyright © 2020 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Javelot</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Établissement Public de Santé Alsace Nord, Brumath, France; Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorca</LastName><ForeName>P-M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France; Service Pharmacie, CHU de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fossati</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de psychiatrie adultes, APHP, Sorbonne université, Groupe Hospitalier Pitié Salpêtrière, ICM, Inserm U1127, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haffen</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service de psychiatrie, CIC-1431 Inserm, CHU de Besançon, Laboratoire de Neurosciences, Université de Franche-Comté, Besançon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Enjeux de l’utilisation des psychotropes dans le cadre de la pandémie au SARS-Cov-2.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012119" MajorTopicYN="N">Respiration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Psychotropes</Keyword><Keyword MajorTopicYN="N">Psychotropics</Keyword><Keyword MajorTopicYN="N">Recommandations</Keyword><Keyword MajorTopicYN="N">Recommendations</Keyword><Keyword MajorTopicYN="N">SARS-Cov-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32360037</ArticleId><ArticleId IdType="pii">S0013-7006(20)30077-4</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7177137</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Alsace (région administrative)</li><li>Bourgogne-Franche-Comté</li><li>Franche-Comté</li><li>Grand Est</li><li>Île-de-France</li></region><settlement><li>Besançon</li><li>Paris</li><li>Strasbourg</li></settlement><orgName><li>Université de Franche-Comté</li><li>Université de Strasbourg</li></orgName></list><tree><country name="France"><region name="Grand Est"><name sortKey="Javelot, H" sort="Javelot, H" uniqKey="Javelot H" first="H" last="Javelot">H. Javelot</name></region><name sortKey="Fossati, P" sort="Fossati, P" uniqKey="Fossati P" first="P" last="Fossati">P. Fossati</name><name sortKey="Haffen, E" sort="Haffen, E" uniqKey="Haffen E" first="E" last="Haffen">E. Haffen</name><name sortKey="Llorca, P M" sort="Llorca, P M" uniqKey="Llorca P" first="P-M" last="Llorca">P-M Llorca</name><name sortKey="Meyer, G" sort="Meyer, G" uniqKey="Meyer G" first="G" last="Meyer">G. Meyer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000195 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000195 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32360037
|texte= [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32360037" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |